There's no doubt that appropriate selection of patients for PSMA targeted radioligand therapy is dependent on appropriate imaging. Telix wishes to acknowledge collaboration with Novartis to deliver this outcome to patients.ĭr Oliver Sartor, Medical Director at Tulane Cancer Center, added, 'As radioligand therapy for prostate cancer becomes more prevalent, it is critical for doctors to understand who may or may not respond to those treatments.

Use of Illuccix in the VISION Phase III study ( Identifier: NCT03511664) helped doctors detect prostate cancer and identify the appropriate patients for PSMA-based radioligand therapy. Clinicians now have the ability to use Illuccix in more stages of the patient journey, to confidently and accurately detect and help manage this disease.'

This additional indication further demonstrates our continued commitment to support patients fighting prostate cancer and to empower the doctors who treat them. Kevin Richardson, Chief Executive Officer for Telix Americas said, 'We welcome the FDA's decision to expand the label indication for Illuccix. Īs the only diagnostic agent for prostate cancer that combines the accuracy of gallium imaging with the reliability and flexibility of Telix's distribution network, the expanded indication for Illuccix has the potential to improve access to imaging for patients who are candidates for radioligand therapy. To qualify for radioligand therapy, patients must be imaged with an approved gallium-based PSMA-PET agent. to identify and select patients who are candidates for the only FDA-approved prostate-specific membrane antigen (PSMA)- directed radioligand therapy (Pluvicto ), providing doctors with critical information to guide patient management and help optimise treatment outcomes. The label expansion means Illuccix is now approved in the U.S.

Product key for word 2021